VIRALEX

Indications

• Neuroprotection
• Cardioprotection
• Anti-inflammatory conditions
• Immunomodulation

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Inosine has been found to promote axon growth in vivo, potentially acting as an agonist for nerve growth factor-activated protein kinase (N-Kinase). It may also convert to cyclic nucleotides that help nerve endings overcome myelin inhibitory effects. Additionally, inosine has exhibited positive inotropic effects on cardiac muscle, mild coronary vasodilation, and enhanced myocardial carbohydrate uptake, while also inhibiting production of proinflammatory cytokines in immune cells.

Pharmacodynamics

Inosine may possess neuroprotective, cardioprotective, anti-inflammatory, and immunomodulatory properties. These activities suggest its potential therapeutic applications in conditions involving nerve damage and inflammation.

Pharmacokinetics

The pharmacokinetics of inosine, including absorption, distribution, metabolism, and excretion, are not extensively detailed in the provided sources. Further studies would be necessary to clarify these aspects.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Inosine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether inosine is excreted in human milk. Caution should be exercised when inosine is administered to a nursing woman.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Herpes simplex virus infections
• Human papillomavirus infections
• Other viral infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to specific guidelines or the BNF for appropriate dosing information.

Mechanism of action

Pranobex exerts its effects by enhancing the immune response to viral infections. It increases the synthesis of interferon and other cytokines, which are crucial for the antiviral immune response. Additionally, it may inhibit viral replication by interfering with nucleic acid synthesis in infected cells.

Pharmacodynamics

Pranobex's pharmacodynamic properties include its ability to enhance both humoral and cell-mediated immune responses. It activates lymphocytes and promotes the production of antibodies, which contribute to the body's defense against viral infections. The drug also exhibits direct antiviral activity against certain viruses by inhibiting their replication.

Pharmacokinetics

Pranobex is well absorbed after oral administration, with peak plasma concentrations achieved within a few hours. It is metabolized in the liver, and its metabolites are excreted primarily via the kidneys. The elimination half-life is typically a few hours, necessitating multiple doses to maintain effective therapeutic levels in the body.

Contra-indications

• Hypersensitivity to pranobex or any of its components
• Severe liver dysfunction
• Active autoimmune diseases

Adverse effects

• Gastrointestinal disturbances
• Rash or other allergic reactions
• Headache
• Dizziness
• Fatigue
• Liver enzyme elevation

Interactions

• May enhance the effects of immunosuppressive drugs
• Potential interaction with anticoagulants leading to increased bleeding risk
• May affect the metabolism of certain drugs processed by the liver

Precautions

• Use cautiously in patients with liver impairment
• Monitor liver function periodically
• Assess for signs of hypersensitivity reactions
• Evaluate the risk of bleeding in patients taking anticoagulants

Pregnancy

Limited data on the safety of pranobex in pregnancy; use only if potential benefits justify the potential risks to the fetus.

Breast-feeding

Limited information available; consider the benefits of breastfeeding alongside the potential risks of drug exposure.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablet
• Oral suspension

Mechanism of action

Inosine has been found to have potent axon-promoting effects in vivo following unilateral transection of the corticospinal tract of rats. The mechanism of this action is unclear. Possibilities include serving as an agonist of a nerve growth factor-activated protein kinase (N-Kinase), conversion to cyclic nucleotides that enable advancing nerve endings to overcome the inhibitory effects of myelin, stimulation of differentiation in rat sympathetic neurons, augmentation of nerve growth factor-induced neuritogenesis and promotion of the survival of astrocytes, among others. The mechanism of inosine's possible cardioprotective effect is similarly unclear. Inosine has been reported to have a positive inotropic effect and also to have mild coronary vasodilation activity. Exogenous inosine may contribute to the high-energy phosphate pool of cardiac muscle cells and favorably affect bioenergetics generally. Inosine has also been reported to enhance the myocardial uptake of carbohydrates relative to free fatty acids as well as glycolysis. In cell culture studies, inosine has been found to inhibit the production, in immunostimulated macrophages and spleen cells, of the proinflammatory cytokines, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, interleukin (IL)-12, macrophage-inflammatory protein-1 alpha and interferon (IFN)-gamma. It also suppressed proinflammatory cytokine production and mortality in a mouse endotoxemic model. These actions might account for the possible immunomodulatory, anti-inflammatory and anti-ischemic actions of inosine.

Pharmacodynamics

Inosine may have neuroprotective, cardioprotective, anti-inflammatory and immunomodulatory activities.